Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Outpatient at least 12 years of age~* Both genders; females of child bearing potential must be willing to use approved birth control method~* Pre-bronchodilator FEV1 of 40-90% predicted~* Reversibility FEV1 of at least 12% and 200mLs~* Current asthma therapy that includes an inhaled corticosteroid for at least 4 weeks prior to first visit~Exclusion Criteria:~* History of life threatening asthma~* Respiratory infection or candidiasis~* Asthma exacerbation within 6 months prior to first visit~* Concurrent respiratory disease or other disease that would confound study participation or affect subject safety~* Allergies to study drugs, study drug excipients, medications related to study drugs~* Taking another investigational medication or medication prohibited for use during this study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone Furoate OD and Placebo BID (Type: EXPERIMENTAL): Fluticasone furoate inhalation powder once daily and placebo inhalation powder twice daily for 24 weeks
- Fluticasone Propionate BID and Placebo OD (Type: ACTIVE_COMPARATOR): Fluticasone propionate inhalation powder twice daily and placebo inhalation powder once daily for 24 weeks
- Placebo only BID (Type: PLACEBO_COMPARATOR): Placebo inhalation powder twice daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).